Uploaded February 2026 | Updated September 2026, 1 week ago
The AI drug discovery industry is often distracted by "Pinocchio walks"—fancy PowerPoints and star-studded boards that mask a lack of substance. If you want to measure true R&D productivity, stop looking at the hype and start looking at Zero to Developmental Candidate (PCC).
Think of drug discovery like a high-performance sports car:
- The Acceleration (0 to PCC): This is where AI excels. Traditional methods take 4.5 years; we’ve shortened this to an average of 13 months.
- The Traffic (Clinical Trials): Once you hit IND-enabling studies, you are in a highly regulated zone. You must move at the "speed of traffic" dictated by regulators. You cannot "AI" your way out of a 28-day toxicity study.
The Productivity Formula
To compare platforms objectively, use this calculation:
Productivity = Preclinical R&D Budget/Number of PCCs developed x Number of drugs out-licensed
The Ultimate Lie Detector: Out-Licensing
The "Number of drugs out-licensed" is the most critical variable. When a pharmaceutical company licenses your molecule, 70 experts spend months trying to "kill the deal" by finding flaws in your data. If you pass that rigorous scrutiny, your platform is validated.
Benchmark Against Champions
The real "China Speed" is the new global standard. Local biotechs there are discovering drugs at a scale and speed previously unseen. If you want to lead, don't just develop "fancy algorithms" for isolated problems—compete against the champions who are delivering high-quality candidates to the clinic every single year.
Zero to PCC is the only benchmark that matters. Everything else is just moving with the speed of traffic.
The AI drug discovery industry is often distracted by "Pinocchio walks"—fancy PowerPoints and star-studded boards that mask a lack of substance. If you want to measure true R&D productivity, stop looking at the hype and start looking at Zero to Developmental Candidate (PCC).
Think of drug discovery like a high-performance sports car:
- The Acceleration (0 to PCC): This is where AI excels. Traditional methods take 4.5 years; we’ve shortened this to an average of 13 months.
- The Traffic (Clinical Trials): Once you hit IND-enabling studies, you are in a highly regulated zone. You must move at the "speed of traffic" dictated by regulators. You cannot "AI" your way out of a 28-day toxicity study.
The Productivity Formula
To compare platforms objectively, use this calculation:
Productivity = Preclinical R&D Budget/Number of PCCs developed x Number of drugs out-licensed
The Ultimate Lie Detector: Out-Licensing
The "Number of drugs out-licensed" is the most critical variable. When a pharmaceutical company licenses your molecule, 70 experts spend months trying to "kill the deal" by finding flaws in your data. If you pass that rigorous scrutiny, your platform is validated.
Benchmark Against Champions
The real "China Speed" is the new global standard. Local biotechs there are discovering drugs at a scale and speed previously unseen. If you want to lead, don't just develop "fancy algorithms" for isolated problems—compete against the champions who are delivering high-quality candidates to the clinic every single year.
Zero to PCC is the only benchmark that matters. Everything else is just moving with the speed of traffic.
